In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists

European Journal of Pharmacology

Volumn 326, Issue 2-3, 1997, Pages 201-209

  Rupniak, Nadia M J ^a   Tattersall, F David ^a   Williams, Angela R ^a   Rycroft, Wayne ^a   Carlson, Emma J ^a   Cascieri, Margaret A ^b   Sadowski, Sharon ^b   Ber, Elzbieta ^b   Hale, Jeffrey J ^b   Mills, Sander G ^b   MacCoss, Malcolm ^b   Seward, Eileen ^a   Huscroft, Ian ^a   Owen, Simon ^a   Swain, Christopher J ^a   Hill, Raymond G ^a   Hargreaves, Richard J ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anti emetic; Brain penetration; Tachykinin NK1 receptor

Indexed keywords

2 BENZYL 1 (3,5 DIMETHYLBENZOYL) 4 (4 QUINOLINYLMETHYLAMINO)PIPERIDINE; 2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; 5 AMINOVALERYLSUBSTANCE P [7-11][9 PROLINE 10 (N METHYLLEUCINE)]; CISPLATIN; LANEPITANT; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROKININ 1 RECEPTOR; NOLPITANTIUM; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIEMETIC ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CHO CELL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FERRET; GERBIL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

EID: 0030911476     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)85415-5     Document Type: Article

References (51)

1. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs. 42:1991;551.
2. Andrews P.L.R., Bhandari P. The 5-hydroxytryptamine receptor antagonists as anti-emetics: preclinical evaluation and mechanism of action. Eur. J. Cancer. 29A(Suppl. 1):1993;S11-S16.
3. Andrews P.L.R., Rapeport W.G., Sanger G.J. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol. Sci. 9:1988;334-341.
4. 1 receptor antagonist. Br. J. Pharmacol. 116:1995;3149-3157.
5. 1 receptors by use of the non-peptide antagonist, CP-96,345. Br. J. Pharmacol. 104:1991;292-293.
6. 1 receptor antagonist, CP-99,994, in ferrets. Eur. J. Pharmacol. 249:1993;R3-R4.
7. 1 receptor activation in gerbils. Eur. J. Pharmacol. 254:1994;245-249.
8. 3 receptor antagonists as anti-emetics. Trends Pharmacol. Sci. 12:1991;46-48.
9. Butcher M.E. Global experience with ondansetron and future potential. Oncology. 50:1993;191-197.
10. Cascieri M.A., Ber E., Fong T.M., Sadowski S., Bansal A., Swain C., Seward E., Frances B., Burns D., Strader C.D. Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor. Mol. Pharmacol. 42:1992;458-463.
11. Cascieri M.A., Chichi G.G., Ling T.M. Demonstration of two distinct tachykinin receptors in rat brain cortex. J. Biol. Chem. 260:1985;1501-1507.
12. De Mulder P.H.M., Seynaeve C., Vermorken J.B., Van Liessum P.A., Mols-Jevdevic S., Allman E.L., Beranek P., Verwejj J. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann. Intern. Med. 113:1990;834-840.
13. Dionne R.A., Max R.B., Parada S., Gordon S.M., MacLean D.B. Evaluation of a neurokinin-1 antagonist, CP-99,994, in comparison to ibuprofen and placebo in the surgery model. Clin. Pharmacol. Ther. 59:1996;216.
14. 1 receptor antagonist. Eur. J. Pharmacol. 250:1993;403-413.
15. 1 antagonist RPR100893 using an ex vivo binding assay in the guinea-pig. Br. J. Pharmacol. 116:1995;252P.
16. 1 receptor antagonists is mediated centrally in the ferret. Br. J. Pharmacol. 112:1994;516P.
17. 1 receptor antagonist GR203040. Br. J. Pharmacol. 116:1995;3158-3163.
18. Gitter B.D., Bruns R.F., Howbert J.J., Waters D.C., Threlkeld P.G., Cox L.M., Noxon J.A., Lobb K.L., Mason N.R., Stengel P.W., Cockerham S.L., Silbaugh S.A., Gehlert D.R., Schober D.A., Iyengar J., Calligaro D.O., Regoli D., Hipskind P.A. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist. J. Pharmacol. Exp. Ther. 275:1995;737-744.
19. Gonsalves S., Watson J., Ashton C. Broad spectrum antiemetic effects of CP-122,721, a tachykinin receptor antagonist, in ferrets. Eur. J. Pharmacol. 305:1996;181-185.
20. Graham E.A., Turpin M.P., Stubbs C.M. Characterisation of the tachykinin-induced hindlimb thumping response in gerbils. Neuropeptides. 4:1993;228.
21. Hagan R.M., Ireland S.J., Jordan C.C., Beresford I.J.M., Deal M.J., Ward P. Receptor-selective peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: new tools for investigating neurokinin function. Neuropeptides. 19:1991;127-132.
22. Hagiwara D., Miyaka H., Igari N., Murano K., Morimoto H., Murai M., Fuji T., Matsuo M. Design of a novel dipeptide substance P antagonist FK888. Regul. Pept. 46:1993;332-334.
23. 1 receptor antagonist. J. Med. Chem. 39:1996;1760-1762.
24. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br. J. Pharmacol. 97:1989;247-255.
25. 1 antagonist with a long duration of action. Presented at Tachykinins '95: From Basic Science to Clinical Applications, Florence.
26. 1 receptors. Neuropharmacology. 33:1994;167-179.
27. Kris M.G., Redford J., Pizzo B., Insbiner R., Lovelace J., Casey M., Hesketh P. Dose ranging antiemetic trial of the NK-1 receptor antagonist CP-122,721: a new approach for acute and delayed emesis following cisplatin. Proc. Am. Soc. Clin. Oncol. 15:1996;547.
28. Longmore J., Swain C.J., Hill R.G. Neurokinin receptors. Drug News Perspect. 8:1995;5-12.
29. 1 receptor. J. Pharmacol. Exp. Ther. 267:1993;472-479.
30. 1 receptor. J. Pharmacol. Exp. Ther. 277:1996;900-908.
31. Milano S., Blower P., Romain D., Grelot L. The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis. J. Pharmacol. Exp. Ther. 274:1995;951-961.
32. Nagahisa A., Asai R., Kanai Y., Murase A., Tsuchiya-Nakagaki M., Nakagaki T., Shieh T.-C., Taniguchi K. Non-specific activity of (±)-CP-96,345 in models of pain and inflammation. Br. J. Pharmacol. 107:1992;273-275.
33. 3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology. 33:1994;1607-1608.
34. Rudd J.A., Jordan C.C., Naylor R.J. Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis. Eur. J. Pharmacol. 262:1994;R1-R2.
35. 1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br. J. Pharmacol. 119:1996;931-936.
36. 1 receptor antagonists. Eur. J. Pharmacol. 265:1994;179-183.
37. 1 receptor antagonist CP-99,994, in conscious gerbils. Br. J. Pharmacol. 116:1995;1937-1943.
38. 1 receptor antagonist L-733,060 in gerbils. Pain. 67:1996;189-195.
39. 3 Receptors. Academic Press, London, pp. 207-220.
40. 1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology. 34:1995;255-261.
41. 1 receptor antagonist, CP-99,994, in antinociceptive tests in rat, mouse and gerbil. Eur. J. Pharmacol. 271:1994;481-487.
42. 1) receptor antagonist in painful peripheral neuropathy. Neurology. 44(Suppl. 2):1994;A220.
43. 1 antagonists: the triarylperhydroisoindols. Bioorg. Med. Chem. Lett. 4:1994;673.
44. 1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur. J. Pharmacol. 250:1993;R5-R6.
45. 1 receptor antagonist CP-99,994. Neuropharmacology. 33:1994;259-260.
46. 1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 35:1996;1121-1129.
47. 1 receptor antagonist: behavioural effects. Neuropeptides. 26(Suppl. 1):1994;38.
48. 1 antagonists: a new approach to the treatment of emesis. Discovery of a potent, orally bioavailable drug candidate. 8th RSC-SCI Medicinal Chemistry Symposium, Cambridge, UK.
49. 1 receptor. Br. J. Pharmacol. 115:1995;84-94.
50. Watson, J.W., Nagahisa, A., Lucot, J.B., Andrews, P.L.R., 1995b. The tachykinins and emesis: towards complete control? In: Reynolds, D.J.M., Andrews, P.L.R., Davis, C.J. (Eds.), Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford Clinical Communications, Oxford, pp. 233-238.
51. Yarker Y.E., McTavish D. Granisetron: an update on its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs. 48:1994;761-767.